- MSNs offer high surface area, tunable pores and facile surface functionalisation for efficient cargo loading, overcoming solubility, stability and targeting limitations.
- Controllable synthesis and structural engineering of MSNs enable multimodal imaging and diverse therapies including chemo, dynamic, thermal and gas therapy, plus tissue engineering.
- Clinical translation challenges include biological barriers such as the blood-brain barrier, bioavailability, systemic toxicity and scalable manufacturing; structure-property insight guides future rational design.
Adv Healthc Mater. 2026 Oct 30:e71928. doi: 10.1002/adhm.71928. Online ahead of print.
ABSTRACT
The increasing global burden of severe diseases, such as cancers, cardiovascular and neurodegenerative disorders, highlights the urgent need for advanced diagnostic and therapeutic agents. Although techniques like computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and chemotherapy show promise, their effectiveness is frequently constrained by the inherent drawbacks of conventional agents, such as poor solubility, low stability, and lack of targeting ability, as well as physiological barriers like the blood-brain barrier (BBB), which limit bioavailability and induce systemic toxicity. Mesoporous silica nanoparticles (MSNs) have emerged as promising platforms to overcome these challenges, offering high surface area, tunable pore size, and facile surface functionalization for efficient cargo loading. Therefore, in this work, the recent advances in the synthesis, structural control, and functional design of MSNs-based composites are systematically reviewed, with a focus on their biomedical applications in diagnosis (e.g., fluorescence imaging (FLI)/MRI/PET), therapy (e.g., chemo-, dynamic, thermal, and gas therapy), and tissue engineering. Key strategies for performance optimization and structure-property relationships are discussed in depth. Finally, we delineate prevailing challenges and future directions for the clinical translation of MSNs-based nanomaterials, providing an integrated perspective to guide their rational design and biomedical implementation.
PMID:42963204 | DOI:10.1002/adhm.71928
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

